An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study. The ...
Angesichts des Drucks der Trump-Regierung hat der Schweizer Pharmariese Roche seine seit langem bestehenden globalen ...
UK biotech Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (I-O) and ...
Swiss pharmaceutical giant Roche is cutting its global diversity workforce targets, aligning with recent U.S. legal changes ...
Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...
A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...
Shamrock Rovers hold a three-point advantage at the summit of the Premier Division after overcoming local rivals Moyne ...
The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.
New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of motor function in a broad population of ...
Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...
Roche’s work in India is powered by its digital centre of excellence, which Jamalamadaka mentioned “operates as an integral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback